Extended Raptiva therapy safe, effective for psoriasis

	Tweet

Treatment with the relatively new drug Raptiva for 12 weeks has been shown to be a safe and effective treatment for moderate-to-severe chronic psoriasis. Now, new research indicates that the benefits are even more pronounced, without an increase in side effects, when therapy is extended to 24 weeks.

The study was sponsored by Genentech, Inc., which markets as Raptiva, known technically as efalizumab.

The findings, which appear in the Archives of Dermatology, are based on a study of 516 psoriasis patients who were given weekly injections of efalizumab or an inactive placebo for 12 weeks, and then efalizumab for 12 additional weeks.

After the first 12 weeks, the proportion of efalizumab-treated patients who achieved a 75% or 50% or greater improvement on a standardized psoriasis severity score was 26.6 percent and 58.5 percent, respectively.

By the 24th week, these numbers had improved to 43.8 percent and 66.6 percent, Dr. Alan Menter, from the Texas Dermatology Research Institute in Dallas, and colleagues report.

Moreover, improvements in symptom scores were maintained throughout the full study period.

There was no evidence of accumulating toxicity during the extension phase of the study, and the rate of reported adverse effects actually fell during the last 12 weeks.

“A longer-term (36-month) maintenance study currently under way will further define the ability to use continuous efalizumab therapy for this lifelong chronic disease,” the researchers note.

SOURCE: Archives of Dermatology, January 2005.

RELATED STORIES:
Skin condition more likely in educated parents’ kids   Choosing the Right Sunscreen   Note to dermatologists: the necktie is out   Tattoos ink may contain heavy metals: study   More evidence that caffeine lowers risk of skin cancer   Plaque Psoriasis   Eye color may indicate risk for serious skin conditions   Laser therapy improves rosacea skin sensitivity   Humira (Adalimumab) Appears to Provide Improvement in Disease Activity, Quality of Life for Patients   Immune drugs useful for psoriasis   Psoriasis my yield to modified anti-anxiety drug   Skim milk linked to acne among teen girls

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]